Trials / Withdrawn
WithdrawnNCT05815186
Ladarixin With Sotorasib in Advanced NSCLC - Phase II
Phase II Study of Ladarixin and Sotorasib In Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- NYU Langone Health · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
Study record has been combined with NCT05815173. See NCT05815173 for summary.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sotorasib | Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles |
| DRUG | Ladarixin | Ladarixin administered twice-daily at the recommended phase II dose (RP2D) (determined in the phase I portion of this trial) over 21-day treatment cycles. |
Timeline
- Start date
- 2024-04-01
- Primary completion
- 2025-04-01
- Completion
- 2026-04-01
- First posted
- 2023-04-18
- Last updated
- 2024-03-29
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05815186. Inclusion in this directory is not an endorsement.